The pathogenesis of multiple sclerosis (MS) involves multiple molecules, including several genes and their products associated with inherited aspects of the disease, and a large number of protein, lipid, and carbohydrate molecules not associated in any obvious manner with genetic susceptibility. Molecules participating in the pathology of MS include those with known roles in inflammation and those with known roles in degenerative processes including neuronal and glial viability. Other molecules involved in pathogenesis have no known roles in either inflammation or degeneration. Understanding the complex interplay of these molecules is likely to produce major insights into the pathogenesis of MS, including the elucidation of new drug targets, and the development of biomarkers to predict outcome and to warn of impending troubles. Nearly, one decade into the 21st century great uncertainty still reigns about the details of how various molecular pathways are involved in the pathogenesis of various stages of MS. An exciting study by Satoh et al. [1] used a newly emerging approach termed systems biology to identify molecular networks and pathways at various stages of MS [2] .
Satoh et al. used an existing comprehensive dataset of proteins, isolated from three distinct types of MS brain lesions; acute plaque (AP), chronic active plaque (CAP), and chronic plaque (CP) [3] . The data set was the result of the first detailed study of the proteins found these lesion types from MS brain. This set of proteins was isolated after laser-capture microdissection of well-defined MS lesions. The specimens were then analyzed with another cutting edge technology, proteomics, which relies on separation of proteins, cleavage of such proteins into component peptide fragments, and then characterization of these proteins via mass spectroscopy. The work by Satoh et al. is of considerable interest. It shows molecular pathways unique to each disease stage using bioinformatic tools to help unravel the molecular pathogenesis of this complex disease.
MS is a chronic, often relapsing, inflammatory demyelinating condition where intricate interaction between central nervous system and the immune system occurs [4] . The initial stages of the immune attack during MS include significant immune cell infiltration and destruction of myelin-containing tissue of the central nervous system. This stage is followed by the simultaneous occurrence of inflammation and attempts at intrinsic repair. As inflammation subsides, the repair processes involving glial cells and even neurons take over. These events are demonstrated by histopathological changes within AP, CAP, and CP lesions in the white matter of MS brains [3] . Molecular changes that occur during these stages have also been clearly demonstrated by several groups [5] [6] [7] .
Elucidation of the pathogenesis of a complex disease like MS warrants such a systems biology approach to identify groups or clusters of molecules involved in these remarkable biological events. Earlier studies of peripheral blood monocytes with large scale profiling of peripheral blood lymphocytes from MS patients have identified molecular networks in pathogenesis, as well as networks that are involved in the favorable or unfavorable response to therapy [8] . The study by Satoh et al. is the first to identify molecular networks involving MS brain lesions.
In this study, Satoh et al. focused on a MS-lesion specific proteome to identify distinct networks that occur during AP, CAP, and CP lesion formation. Using four different tools for pathway analysis of bioinformatics and database search, the authors identified extra-cellular matrix (ECM)-mediated focal adhesion, integrin signaling, cytokine pathways, and molecules involved in cell-cell contact as crucial networks in the CAP and CP proteomes.
The extracellular matrix and integrin signaling are of course well-known to those who have studied relapsing-remitting MS. α4β1 integrin is the key molecule involved in homing of lymphocytes to the central nervous system, and its blockade is the mechanism whereby Natalizumab works to inhibit lymphocyte homing [9] [10] [11] . Perhaps, less wellknown is osteopontin, a member of the SIBLING family of small integrin-binding proteins, which bind α4β1 integrin. Osteopontin is an intriguing protein which is present in soluble form in blood bound to the complement inhibitor Factor H, while it is also an extracellular matrix protein. Osteopontin is elevated at the time of relapse [12] [13] [14] . Osteopontin infusion can trigger experimental relapses [15] .
Findings from this study raise several interesting questions. Different bioinformatic tools favor certain pathways and de-emphasize or ignore others. There are different filtering mechanisms used in different software aimed at highlighting so-called "pathways." The Satoh study used software that somehow did not identify pathways such as NFkB and MAPK pathways that are known to be crucial in the pathogenesis of MS [16, 17] . This could be explained in part by the study design of the original proteomic analysis, which focused on high abundance proteins, and thus may have excluded low-abundance signaling molecules. This could be overcome by modifying the mass spectrometric analysis to include such low-abundance proteins [18] . Furthermore, it would be useful to integrate various proteomic datasets with several different platforms (such as mRNA transcripts, lipids, antibodies). This would expand the ability to highlight different aspects of key signaling pathways.
The MAPK pathways are linked to molecules like Ras and Rho, which must be farnesylated or geranylated to begin signal transduction from the membrane [19] . An analysis which includes changes in levels of isoprenoids might be critical in such analyses. Integration of various large-scale platforms including proteomics, transcriptomics, and lipidomics would overcome methodological limitations. One must take account of the biochemistry of molecules in question. A full picture of the role of a particular molecule emerges, when one considers the half-life of the molecule in terms of both its activity before degradation and its pharmacodynamic effects even after degradation, its relative abundance, its cellular localization, and its post-translational modifications. Such an integrated approach would illuminate crucial biological events and yield a comprehensive understanding of disease pathogenesis. Any single technique taken in isolation is not fully suitable to do this. Pathways are not merely a succession of proteins: small molecules, sugars, lipids, microRNA, tRNA are all key elements in the orchestration of what we call pathways. Krebs cycle would never be a focus of a proteomic analysis, yet one of its components, fumarate is a key new target in MS [20] .
This study has taken major strides to understand the complex disease we call MS by connecting the pathways from an existing protein database with the aid of bioinformatic tools. This work is an example of taking an unbiased molecular basis approach to disease evolution during certain stages of MS. On a more practical level, this work supports the use of the "new" field of Systems Biology, where we use multiple tools to assess biological functionality, realizing that pathways are multi-level structures [2, 21] .
